Novozymes
kr 416.00Change from previous close: +0.73%Absolute change: +kr 3.00
At a glance
- Revenue growth
- +8.45%
- 2025 vs 2024
- Net income growth
- +90.84%
- 2025 vs 2024
- Net margin
- 14.0%
- 2024: 8.0%
Financial data
Amounts in millions of EUR; per-share values in EUR; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | 1,222 | 1,020 | 557 | 539 | 546 |
| Depreciation and amortization | 575 | 544 | 186 | 183 | 172 |
| Capital expenditure | -410 | -338 | -249 | -371 | -144 |
| Investing cash flow | -1,971 | -200 | -286 | -359 | -369 |
| Financing cash flow | 753 | -703 | -254 | -168 | -213 |
| Dividends paid | -403 | -250 | -379 | -205 | -197 |
| Share repurchases | -99.9 | 0.0 | 0.0 | -67.2 | -202 |
| Debt issued | 1,717 | 135 | 442 | 314 | 330 |
| Debt repaid | -505 | -540 | -335 | -232 | -186 |
| Effect of exchange rates | -8.6 | 13.3 | -7.4 | -0.8 | 7.1 |
| Net change in cash | -4.7 | 130 | 10.0 | 10.5 | -29.3 |
| Free cash flow | 812 | 682 | 308 | 168 | 402 |
| Levered free cash flow | 772 | 465 | 283 | 77.3 | 266 |